Methodist expands access to COVID-19 monoclonal antibody therapies

MEMPHIS, Tenn. — Methodist Le Bonheur Healthcare has expanded access to COVID-19 monoclonal antibody (mAb) therapies at two locations - Methodist University Hospital and Methodist Monoclonal Infusion Center Hacks Cross.

MLH is the first provider in Tennessee to join this national initiative as part of a federal effort to help end COVID-19 and improve health equity in underserved communities, according to a release from Methodist.

Current infusion hours of operation for Methodist University are Monday through Friday, 8 a.m. to 4 p.m., and Monday through Saturday, 8 a.m. to 6 p.m. at the Methodist Infusion Center at Hacks Cross. MLH’s infusion centers have the ability to extend hours of operation to seven days a week, 8 a.m. to 8 p.m., if needed.

To confirm eligibility for mAb therapy and to book an appointment, patients should call 901-516-2255. No physician referral is needed, according to the release.

MLH has administered about 3,000 mAb infusion since December 2020, with the majority of infusions administered since August 2021. As a result of this initiative, MLH will be able to treat up to 1,000 patients per week as needed.

The mAb therapy is the first COVID-19 treatment granted emergency use authorization by the U.S. Food and Drug Administration for outpatient use, according to the release.

A Phase 3 clinical trial showed that the antibody therapy reduced the risk of hospitalization or death by up to 70% in patients who received the drug intravenously compared to those who received a placebo.